Urech K, Scher JM, Hostanska K, et al. Apoptosis inducing activity of viscin, a lipophilic extract from
J Pharm Pharmacol. 2005;57:101-9.
Harmsma M, Gromme M, Ummelen M, et al. Differential effects of
extract IscadorQu on cell cycle progression and apoptosis in cancer cells.
Int J Oncol. 2004;25:1521-1529.
Duong Van Huyen JP, Delignat S, Kazatchkine MD, et al. Comparative study of the sensitivity of lymphoblastoid and transformed monocytic cell lines to the cytotoxic effects of
extracts of different origin.
Yoon TJ, Yoo YC, Kang TB, et al. Antitumor activity of the Korean mistletoe lectin is attributed to activation of macrophages and NK cells.
Arch Pharm Res. 2003;26:861-867.
Mengs U, Gothel D, Leng-Peschlow E. Mistletoe extracts standardized to mistletoe lectins in oncology: review on current status of preclinical research.
Anticancer Res. 2002;22:1399-407.
Ernst E, Schmidt K, Steuer-Vogt MK. Mistletoe for cancer?
Int J Cancer. 2003;107:262-267.
Bock PR, Friedel WE, Hanisch J, et al. Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (
L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland [in German].
Klopp R, Schmidt W, Werner E, et al. Influence of complementary
(Iscador) administration on microcirculation and immune system of ear, nose and throat carcinoma patients treated with radiation and chemotherapy.
Anticancer Res. 2005;25:601-10.
Augustin M, Bock PR, Hanisch J, et al. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (
L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
Kovacs E. Effects of
extract therapy in patients with cancer: relation with interleukin-6, soluble interleukin-6 receptor, and soluble gp130.
J Altern Complement Med. 2004;10:241-6.
Orhan DD, Aslan M, Sendogdu N, et al. Evaluation of the hypoglycemic effect and antioxidant activity of three
subspecies (European mistletoe) in streptozotocin-diabetic rats.
J Ethnopharmacol. 2005;98:95-102.
Onal S, Timur S, Okutucu B, et al. Inhibition of alpha-glucosidase by aqueous extracts of some potent antidiabetic medicinal herbs.
Prep Biochem Biotechnol. 2005;35:29-36.
Gray AM, Flatt PR. Insulin-secreting activity of the traditional antidiabetic plant
Swanson-Flatt SK, Day C, Bailey CJ, Flatt PR. Evaluation of traditional plant treatments for diabetes: studies in streptozotocin-diabetic mice.
Acta Diabetologica Latina. 1989;26:51-55.
Huber R, Klein R, Ludtke R, et al. Frequency of the common cold in healthy subjects during exposure to a lectin-rich and a lectin-poor mistletoe preparation in a randomized, double-blind, placebo-controlled study.
Forsch Komplementarmed Klass Naturheilkd. 2001;8:354-358.
Karagoz A, Onay E, Arda N, et al. Antiviral potency of mistletoe (
ssp. album) extracts against human parainfluenza virus type 2 in Vero cells.
Phytother Res. 2003;17:560-562.
Bauer C, Oppel T, Rueff F, et al. Anaphylaxis to viscotoxins of mistletoe (
Viscum album) extracts.
Ann AllergyAsthma Immunol. 2005;94:86-89.
Harvey J, Colin-Jones DG. Mistletoe hepatitis.
Br Med J (Clin Res Ed). 1981;282:186-187.
Spiller HA, Willias DB, Gorman SE, Sanftleban J. Retrospective study of mistletoe ingestion.
Krenzelok EP, Jacobsen TD, Aronis J. American mistletoe exposures.
Am J Emerg Med
Schink M, Troger W, Dabidian, A, et al. Mistletoe extract reduces the surgical suppression of natural killer cell activity in cancer patients: a randomized phase III trial.
Forsch Komplementarmed. 2007;14:9-17.
Grossarth-Maticek R, Ziegler R. Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador).
Horneber MA, Bueschel G, Huber R, Linde K, Rostock M. Mistletoe therapy in oncology.
Cochrane Database of Systematic Reviews.
Grossarth-Maticek R, Ziegler R. Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of Corpus uteri cancer patients with a mistletoe preparation (Iscador).
Eur J Med Res.
Ostermann T, Raak C, Büssing A. Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review.
Kim KC, Yook JH, et al. Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma - a randomized, controlled pilot study.
BMC Complement Altern Med. 2012;12:172.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.